Meta-analysis of 9 studies (684 patients) with HER2-positive breast cancer brain metastases on trastuzumab deruxtecan: pooled ILD/pneumonitis 10% (grade 3 or higher 2%), leading to discontinuation in 11%; no fatal ILD was reported.
Meta-analysisn = 684
Ma et al. The safety of trastuzumab deruxtecan (T-DXd) in breast cancer brain metastases with a focus on interstitial lung disease/pneumonitis: A systematic review and meta-analysis